Literature DB >> 30288344

Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Reza Mirzaei1, Susobhan Sarkar1, Lauren Dzikowski1, Khalil S Rawji1, Lubaba Khan2, Andreas Faissner3, Pinaki Bose2, V Wee Yong1.   

Abstract

The dismal prognosis of glioblastoma is attributed in part to the existence of stem-like brain tumor-initiating cells (BTICs) that are highly radio- and chemo-resistant. New approaches such as therapies that reprogram compromised immune cells against BTICs are needed. Effective immunotherapies in glioblastoma, however, remain elusive unless the mechanisms of immunosuppression by the tumor are better understood. Here, we describe that while the conditioned media of activated T lymphocytes reduce the growth capacity of BTICs, this growth suppression was abrogated in live co-culture of BTICs with T cells. We present evidence that BTICs produce the extracellular matrix protein tenascin-C (TNC) to inhibit T cell activity in live co-culture. In human glioblastoma brain specimens, TNC was widely deposited in the vicinity of T cells. Mechanistically, TNC inhibited T cell proliferation through interaction with α5β1 and αvβ6 integrins on T lymphocytes associated with reduced mTOR signaling. Strikingly, TNC was exported out of BTICs associated with exosomes, and TNC-depleted exosomes suppressed T cell responses to a significantly lesser extent than control. Finally, we found that circulating exosomes from glioblastoma patients contained more TNC and T cell-suppressive activity than those from control individuals. Taken together, our study establishes a novel immunosuppressive role for TNC associated with BTIC-secreted exosomes to affect local and distal T lymphocyte immunity.

Entities:  

Keywords:  adaptive immunity; cancer stem cells; exosome; extracellular matrix; glioma

Year:  2018        PMID: 30288344      PMCID: PMC6169571          DOI: 10.1080/2162402X.2018.1478647

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  57 in total

1.  The extracellular matrix molecule tenascin C modulates expression levels and territories of key patterning genes during spinal cord astrocyte specification.

Authors:  Michael Karus; Bernd Denecke; Charles ffrench-Constant; Stefan Wiese; Andreas Faissner
Journal:  Development       Date:  2011-11-09       Impact factor: 6.868

2.  A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorylation.

Authors:  E Ashkenazi; M Deutsch; R Tirosh; A Weinreb; A Tsukerman; C Brodie
Journal:  Neuroimmunomodulation       Date:  1997 Jan-Feb       Impact factor: 2.492

3.  Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.

Authors:  Koteswara Rao Garikapati; Nibedita Patel; Venkata Krishna Kanth Makani; Priyanka Cilamkoti; Utpal Bhadra; Manika Pal Bhadra
Journal:  Biochem Biophys Res Commun       Date:  2017-01-17       Impact factor: 3.575

4.  Clinical impact and functional aspects of tenascin-C expression during glioma progression.

Authors:  Christel Herold-Mende; Margareta M Mueller; Mario M Bonsanto; Horst Peter Schmitt; Stefan Kunze; Hans-Herbert Steiner
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

5.  Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.

Authors:  Elena Jachetti; Sara Caputo; Stefania Mazzoleni; Chiara Svetlana Brambillasca; Sara Martina Parigi; Matteo Grioni; Ignazio Stefano Piras; Umberto Restuccia; Arianna Calcinotto; Massimo Freschi; Angela Bachi; Rossella Galli; Matteo Bellone
Journal:  Cancer Res       Date:  2015-03-25       Impact factor: 12.701

Review 6.  Immune defects observed in patients with primary malignant brain tumors.

Authors:  A R Dix; W H Brooks; T L Roszman; L A Morford
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

7.  Glioma-derived extracellular vesicles selectively suppress immune responses.

Authors:  Justin E Hellwinkel; Jasmina S Redzic; Tessa A Harland; Dicle Gunaydin; Thomas J Anchordoquy; Michael W Graner
Journal:  Neuro Oncol       Date:  2015-09-18       Impact factor: 12.300

8.  Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.

Authors:  Weiying Zhou; Miranda Y Fong; Yongfen Min; George Somlo; Liang Liu; Melanie R Palomares; Yang Yu; Amy Chow; Sean Timothy Francis O'Connor; Andrew R Chin; Yun Yen; Yafan Wang; Eric G Marcusson; Peiguo Chu; Jun Wu; Xiwei Wu; Arthur Xuejun Li; Zhuo Li; Hanlin Gao; Xiubao Ren; Mark P Boldin; Pengnian Charles Lin; Shizhen Emily Wang
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

9.  Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.

Authors:  Rossana Domenis; Daniela Cesselli; Barbara Toffoletto; Evgenia Bourkoula; Federica Caponnetto; Ivana Manini; Antonio Paolo Beltrami; Tamara Ius; Miran Skrap; Carla Di Loreto; Giorgia Gri
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  31 in total

1.  The role of exosomes in tumor immunity.

Authors:  Huayu Yang; Lejia Sun; Yilei Mao
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence.

Authors:  Michael W Graner
Journal:  Annu Rev Genomics Hum Genet       Date:  2019-04-12       Impact factor: 8.929

3.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

Review 4.  Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma.

Authors:  Lizhi Pang; Fatima Khan; Amy B Heimberger; Peiwen Chen
Journal:  Trends Cancer       Date:  2022-05-24

Review 5.  Revisiting the Tenascins: Exploitable as Cancer Targets?

Authors:  Richard P Tucker; Martin Degen
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

Review 6.  Glycomaterials to Investigate the Functional Role of Aberrant Glycosylation in Glioblastoma.

Authors:  Chaitanya Tondepu; Lohitash Karumbaiah
Journal:  Adv Healthc Mater       Date:  2021-12-29       Impact factor: 11.092

7.  Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes.

Authors:  Juliana Hofstatter Azambuja; Nils Ludwig; Saigopalakrishna Yerneni; Aparna Rao; Elizandra Braganhol; Theresa L Whiteside
Journal:  Neurooncol Adv       Date:  2020-05-06

Review 8.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

Review 9.  Exosomes and Cancer Stem Cells in Cancer Immunity: Current Reports and Future Directions.

Authors:  Na-Kyeong Lee; Vinoth Kumar Kothandan; Sangeetha Kothandan; Youngro Byun; Seung-Rim Hwang
Journal:  Vaccines (Basel)       Date:  2021-05-01

10.  Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection.

Authors:  Ana Pires; Alexander Greenshields-Watson; Emma Jones; Andrew Godkin; Awen Gallimore; Kathryn Smart; Sarah N Lauder; Michelle Somerville; Stefan Milutinovic; Howard Kendrick; James P Hindley; Rhiannon French; Matthew J Smalley; William J Watkins; Robert Andrews
Journal:  Cancer Immunol Res       Date:  2020-10-06       Impact factor: 12.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.